|
NCCN Guidelines® Insights - Small Cell Lung Cancer, Version 2.2026 |
1.00 |
01/10/2026 - 12:00am to 01/10/2027 - 11:59pm |
|
NCCN Guidelines® Insights - Soft Tissue Sarcoma, Version 1.2025 |
1.00 |
12/10/2025 - 12:00am to 12/10/2026 - 11:59pm |
|
NCCN Guidelines® Insights - Survivorship, Version 3.2026 |
1.00 |
08/10/2026 - 12:00am to 08/10/2027 - 11:59pm |
|
NCCN Optimizing Patient Outcomes - Management of Bispecific T-Cell Engager Toxicities: How to Balance Increased Efficacy with Notable Toxicity |
1.00 |
07/08/2026 - 12:00am to 01/04/2027 - 11:59pm |
|
NCCN Optimizing Patient Outcomes - Precision Immune Targeting: The Rise of Bispecifics in Multiple Myeloma |
1.00 |
09/03/2026 - 12:00am to 01/31/2027 - 11:59pm |
|
NCCN Optimizing Patient Outcomes - Small Cell Lung Cancer: Is Immunotherapy Moving the Needle? |
1.00 |
06/04/2026 - 12:00am to 11/22/2026 - 11:59pm |
|
NCCN Tumor Boards: Induction Therapy for Ph+ B-Cell Acute Lymphoblastic Leukemia |
1.00 |
07/08/2026 - 12:00am to 12/27/2026 - 11:59pm |
|
NCCN Tumor Boards: Management of Early-Stage, Invasive, Non-Metastatic Breast Cancer |
1.00 |
08/07/2026 - 12:00am to 01/17/2027 - 11:59pm |
|
NCCN Tumor Boards: Molecularly Guided Treatment of Adult Gliomas |
1.00 |
06/04/2026 - 12:00am to 10/26/2026 - 11:59pm |
|
NCCN Webinar Series - Optimizing Patient Outcomes: Collaborative Perspectives in Oncology |
|
01/21/2026 - 12:00am to 12/30/2027 - 11:59pm |
|
Non-Small Cell Lung Cancer Case Review |
1.50 |
06/15/2026 - 12:00am to 03/01/2027 - 11:59pm |
|
Novel Treatment Options for Hodgkin Lymphoma |
0.75 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
Oncology in a Global Context: Disparities, Opportunities, and Pathways |
0.50 |
06/15/2026 - 12:00am to 03/01/2027 - 11:59pm |
|
Optimizing Cytoreductive Therapy for Polycythemia Vera |
0.50 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
Optimizing First-Line Therapy for Diffuse Large B-Cell Lymphoma |
0.75 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
Facebook
X
LinkedIn
Forward